CLS receives additional guarantee commitments of approximately SEK 5.8 million for warrants of series TO 7 B
Clinical Laserthermia Systems AB ("CLS" or the "Company") has received additional guarantee commitments from external investors of approximately SEK 5.8 million, meaning that the total amount of guarantee commitments (the so-called "top-down guarantee") amounts to a total of SEK 11.2 million, corresponding to approximately 50% of the proceeds of approximately SEK 22.4 million that the Company can contribute through full exercise of the warrants of series TO 7 B ("Issue proceeds").
Subscription undertakings and guarantee commitments
The Company announces that it has increased the amount of top-down guarantee commitments from previously approximately SEK 5.4 million to a total of approximately SEK 11.2 million, corresponding to a total of approximately 50 percent of the Issue proceeds. Subscription commitments from existing owners already amount to approximately SEK 3.3 million, corresponding to approximately 14.6 percent of the Issue proceeds. Neither the subscription undertakings nor the guarantee commitments are secured by bank guarantee, escrow funds, pledging or similar arrangements.
As for the already communicated guarantee commitments, a compensation of 10% will be paid in shares or cash for external investors.
The subscription price per B-share that is subscribed for through exercising the warrants has, in accordance with the terms and conditions for the warrants, been set to SEK 3.68. Complete terms and conditions for the warrants are available on the Company's website, www.clinicallaser.se.
Summary of instructions and important dates
Holders of warrants who wish to exercise warrants to subscribe for B-shares shall give notice regarding such exercise before the end of November 22, 2024. Warrants that have not been exercised on or before November 22, 2024, will expire without value. Holders who do not wish to exercise their warrants may sell them. Trading with warrants is ongoing up to and including November 20, 2024.
Disclosure to investors pursuant to the act (2023:560) on the Screening of Foreign Direct Investments
The Act (2023:560) on the Screening of Foreign Direct Investments ("FDI Act") applies to the Company's operations. In the event that the exercise of warrants would result in an investor, after the investment, directly or indirectly, holding votes representing or exceeding any of the thresholds of 10, 20, 30, 50, 65, or 90 percent of the votes in the Company, the investor is required to notify their investment to the Inspectorate for Strategic Products in accordance with the FDI Act
Advisers
Redeye AB is acting as financial adviser and Foyen Advokatfirma is acting as legal adviser to CLS in connection with the exercise of warrants series TO 7 B. Nordic Issuing AB is acting as issuing agent.
For more information, please contact
Dan J Mogren, CEO Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: [email protected]
About CLS
Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG®|Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se